Protective immunity against challenge with Leishmania (Leishmania) chagasi in beagle dogs vaccinated with recombinant A2 protein

Fernandes, Ana Paula; Costa, Murilo Soares; Coelho, Eduardo Antônio Ferraz; Michalick, Marilene Suzan Marques; Freitas, Érico Tadeu Fraga; Melo, Maria Norma; Tafuri, Wagner Luiz; Resende, Daniela de Melo; Hermont, Vinícius; Abrantes, Christiane de Freitas; Gazzinelli, Ricardo T.

doi:10.1016/j.vaccine.2008.05.095

Cited by 152 publications

(154 citation statements)

References 38 publications

Supporting

Mentioning

140

Contrasting

Unclassified

Order By: Relevance

“…In this study we focused on several proteins previously demonstrated to be protective against VL in animal models, including dogs, and recognized in humans cured from VL (22). The proteins KMP-11 (3), SMT (16), A2 (13,14), and CPB (34,36) were genetically fused to produce a single multiepitope product developed with the goal of achieving a cost-effective product with maximum efficacy. We evaluated protective efficacy of the resulting polyprotein in two different experimental murine leishmaniases, CL and VL.…”

mentioning

confidence: 99%

KSAC, the First Defined Polyprotein Vaccine Candidate for Visceral Leishmaniasis

Goto

Bhatia

Raman

et al. 2011

Clin. Vaccine Immunol.

View full text Add to dashboard Cite

A subunit vaccine using a defined antigen(s) may be one effective solution for controlling leishmaniasis. Because of genetic diversity in target populations, including both dogs and humans, a multiple-antigen vaccine will likely be essential. However, the cost of a vaccine to be used in developing countries must be considered. We describe herein a multiantigen vaccine candidate comprised of antigens known to be protective in animal models, including dogs, and to be recognized by humans immune to visceral leishmaniasis. The polyprotein (KSAC) formulated with monophosphoryl lipid A, a widely used adjuvant in human vaccines, was found to be immunogenic and capable of inducing protection against Leishmania infantum, responsible for human and canine visceral leishmaniasis, and against L. major, responsible for cutaneous leishmaniasis. The results demonstrate the feasibility of producing a practical, cost-effective leishmaniasis vaccine capable of protecting both humans and dogs against multiple Leishmania species.

show abstract

mentioning

confidence: 99%

KSAC, the First Defined Polyprotein Vaccine Candidate for Visceral Leishmaniasis

Goto

Bhatia

Raman

et al. 2011

Clin. Vaccine Immunol.

View full text Add to dashboard Cite

show abstract

“…The A2 recombinant protein from L. donovani has been tested also in vaccine development including a disponible commercial vaccine, Leish-Tec  (CARVALHO et al, 2002;FERNANDES et al, 2008;TESTASICCA et al, 2014). Further research and novel protocols are being developed to obtain a better characterization of this newly expressed recombinant protein.…”

Section: Discussionmentioning

confidence: 99%

Expression of a recombinant protein, A2 family, from Leishmania infantum (Jaboticabal strain) and its evaluation in Canine Visceral Leishmaniasis serological test

Jusi

Oliveira

Nakaghi³

et al. 2015

Rev. Bras. Parasitol. Vet.

View full text Add to dashboard Cite

This study aimed to express a recombinant A2 family protein of Leishmania chagasi, Jaboticabal strain; test this protein as an antigen in serological assays; and investigate its antigenicity and immunogenicity. A protein coded by an allele of the A2 gene isolated from L. chagasi was expressed in three different strains of Escherichia coli. We used 29 sera samples from Leishmune-vaccinated dogs, 482 sera samples from dogs from endemic areas (positive controls), and 170 sera samples from dogs from non-endemic areas (negative controls) in ELISA tests using soluble Leishmaniaantigen (SLA) and His-A2 as antigen. Expressed proteins showed, by western blotting, the expression of an 11 KDa protein. Sixty-three percent (303/482) of the samples from endemic areas were positive by ELISA His-A2, whereas 93.1% (27/29) of Leishmune®-vaccinated animals were negative by His-A2-ELISA. Anti-A2 antibodies from mice inoculated with the A2 protein were detected in slides containing amastigote forms, but not in slides containing promastigote forms. The A2 recombinant protein from L. chagasi may be a useful tool in the diagnosis of CVL, and further tests regarding the infection stage and the specie of parasite at which the dogs are sampled should provide a better understanding of our results.

show abstract

“…It is encoded by a multigene family that is abundantly expressed in the amastigote forms of some Leishmania species able to cause VL (40) . Studies of the administration of recombinant A2 protein associated with immune adjuvants (41) (42) or as a DNA vaccine (43) , as well as in attenuated non-replicative viruses (44) , non-pathogenic bacteria (45) , or non-virulent Leishmania tarentolae (46) , have provided evidence of its protective effi cacy in mammalian models.…”

Section: Second-generation Vaccines Against Visceral Leishmaniasismentioning

confidence: 99%

“…Studies of the administration of recombinant A2 protein associated with immune adjuvants (41) (42) or as a DNA vaccine (43) , as well as in attenuated non-replicative viruses (44) , non-pathogenic bacteria (45) , or non-virulent Leishmania tarentolae (46) , have provided evidence of its protective effi cacy in mammalian models. In general, anti-A2 protective immunity is associated with the generation of parasite-specifi c IgG2a antibodies, as well as with the production of high levels of antileishmanial IFN-γ and low levels of IL-10 by T cells in recall response to the A2 protein or parasite extracts (40) . Other amastigote-specifi c antigens that have been considered promising candidates for VL prevention include the cysteine proteinases (CP).…”

Section: Second-generation Vaccines Against Visceral Leishmaniasismentioning

confidence: 99%

Recent updates and perspectives on approaches for the development of vaccines against visceral leishmaniasis

Duarte

Lage

Martins

et al. 2016

Rev. Soc. Bras. Med. Trop.

View full text Add to dashboard Cite

Visceral leishmaniasis (VL) is one of the most important tropical diseases worldwide. Although chemotherapy has been widely used to treat this disease, problems related to the development of parasite resistance and side effects associated with the compounds used have been noted. Hence, alternative approaches for VL control are desirable. Some methods, such as vector control and culling of infected dogs, are insuffi ciently effective, with the latter not ethically recommended. The development of vaccines to prevent VL is a feasible and desirable measure for disease control; for example, some vaccines designed to protect dogs against VL have recently been brought to market. These vaccines are based on the combination of parasite fractions or recombinant proteins with adjuvants that are able to induce cellular immune responses; however, their partial effi cacy and the absence of a vaccine to protect against human leishmaniasis underline the need for characterization of new vaccine candidates. This review presents recent advances in control measures for VL based on vaccine development, describing extensively studied antigens, as well as new antigenic proteins recently identifi ed using immuno-proteomic techniques.

show abstract

Protective immunity against challenge with Leishmania (Leishmania) chagasi in beagle dogs vaccinated with recombinant A2 protein

Cited by 152 publications

References 38 publications

KSAC, the First Defined Polyprotein Vaccine Candidate for Visceral Leishmaniasis

KSAC, the First Defined Polyprotein Vaccine Candidate for Visceral Leishmaniasis

Expression of a recombinant protein, A2 family, from Leishmania infantum (Jaboticabal strain) and its evaluation in Canine Visceral Leishmaniasis serological test

Recent updates and perspectives on approaches for the development of vaccines against visceral leishmaniasis

Contact Info

Product

Resources

About